21 results
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | As previously reported | Impact of adjustment | As Restated | As previously reported | Impact of adjustment | As Restated | Grant income | $ | — | $ | — | $ | 166 | $ | 166 | License revenue | 1,292 | 1,292 | — | — | Operating expenses: | Research and development | (31,344) | 3,956 | (27,388) | (33,963) | 5,598 | (28,365) | General and administrative | (9,284) | (9,284) | (7,987) | (7,987) | Loss on disposal of property and equipment | (3,768) | (3,768) | — | — | Total operating expenses, net | (43,104) | 3,956 | (39,148) | (41,784) | 5,598 | (36,186) | Other income (expense), net | 782 | 782 | 860 | 860 | Interest income | 3,446 | 3,446 | 28 | 28 | Interest expense | (4,905) | (4,905) | (1,790) | (1,790) | Total other expenses, net | (677) | — | (677) | (902) | — | (902) | Net loss before income tax | (43,781) | 3,956 | (39,825) | (42,686) | 5,598 | (37,088) | Income tax benefit | 3,970 | (3,956) | 14 | 5,624 | (5,598) | 26 | Net loss attributable to ordinary shareholders | (39,811) | — | (39,811) | (37,062) | — | (37,062) | Other comprehensive income (loss): | Foreign currency exchange translation adjustment | 5,641 | 5,641 | (7,455) | (7,455) | Total comprehensive loss | $ | (34,170) | $ | — | $ | (34,170) | $ | (44,517) | $ | — | $ | (44,517) | Basic and diluted net loss per ordinary share | $ | (0.23) | $ | — | $ | (0.23) | $ | (0.41) | $ | — | $ | (0.41) | Weighted-average basic and diluted ordinary shares | 173,825,825 | 173,825,825 | 173,825,825 | 90,914,175 | 90,914,175 | 90,914,175 |
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | As previously reported | Impact of adjustment | As Restated | As previously reported | Impact of adjustment | As Restated | Grant income | $ | — | $ | — | $ | — | $ | — | License revenue | — | — | — | — | Operating expenses: | Research and development | (36,742) | 3,510 | (33,232) | (38,212) | 7,418 | (30,794) | General and administrative | (11,122) | (11,122) | (8,269) | (8,269) | Loss on disposal of property and equipment | (23) | (23) | — | — | Total operating expenses, net | (47,887) | 3,510 | (44,377) | (46,481) | 7,418 | (39,063) | Other income (expense), net | 482 | 482 | (1,331) | (1,331) | Interest income | 3,403 | 3,403 | 89 | 89 | Interest expense | (5,020) | (5,020) | (1,810) | (1,810) | Total other expenses, net | (1,135) | — | (1,135) | (3,052) | — | (3,052) | Net loss before income tax | (49,022) | 3,510 | (45,512) | (49,533) | 7,418 | (42,115) | Income tax benefit (expense) | 3,470 | (3,510) | (40) | 7,474 | (7,418) | 56 | Net loss attributable to ordinary shareholders | (45,552) | — | (45,552) | (42,059) | — | (42,059) | Other comprehensive income (loss): | Foreign currency exchange translation adjustment | 5,300 | 5,300 | (17,485) | (17,485) | Total comprehensive loss | $ | (40,252) | $ | — | $ | (40,252) | $ | (59,544) | $ | — | $ | (59,544) | Basic and diluted net loss per ordinary share | $ | (0.26) | $ | — | $ | (0.26) | $ | (0.46) | $ | — | $ | (0.46) | Weighted-average basic and diluted ordinary shares | 173,860,491 | 173,860,491 | 173,860,491 | 90,931,964 | 90,931,964 | 90,931,964 |
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
Three Months Ended September 30, 2023 | Three Months Ended September 30, 2022 | As previously reported | Impact of adjustment | As Restated | As previously reported | Impact of adjustment | As Restated | Grant income | $ | — | $ | — | $ | — | $ | — | License revenue | 406 | 406 | 2,369 | 2,369 | Operating expenses: | Research and development | (37,237) | 4,919 | (32,318) | (37,632) | 6,147 | (31,485) | General and administrative | (10,611) | (10,611) | (8,231) | (8,231) | Impairment of operating lease right-of-use assets and related property and equipment | (382) | (382) | — | — | Total operating expenses, net | (47,824) | 4,919 | (42,905) | (43,494) | 6,147 | (37,347) | Other income (expense), net | (1,597) | (1,597) | (3,740) | (3,740) | Interest income | 3,646 | 3,646 | 165 | 165 | Interest expense | (5,014) | (5,014) | (1,850) | (1,850) | Total other expenses, net | (2,965) | — | (2,965) | (5,425) | — | (5,425) | Net loss before income tax | (50,789) | 4,919 | (45,870) | (48,919) | 6,147 | (42,772) | Income tax benefit | 4,940 | (4,919) | 21 | 6,152 | (6,147) | 5 | Net loss attributable to ordinary shareholders | (45,849) | — | (45,849) | (42,767) | — | (42,767) | Other comprehensive income (loss): | Foreign currency exchange translation adjustment | (5,837) | (5,837) | (14,054) | (14,054) | Total comprehensive loss | $ | (51,686) | $ | — | $ | (51,686) | $ | (56,821) | $ | — | $ | (56,821) | Basic and diluted net loss per ordinary share | $ | (0.26) | $ | — | $ | (0.26) | $ | (0.47) | $ | — | $ | (0.47) | Weighted-average basic and diluted ordinary shares | 173,984,101 | 173,984,101 | 173,984,101 | 91,240,801 | 91,240,801 | 91,240,801 |
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
Year ended December 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||
As previously Reported | Restatement adjustments | As Restated | Research and development expenses | $ | (141,992) | $ | 24,638 | $ | (117,354) | Total operating expenses, net | (168,046) | 24,638 | (143,408) | Income tax benefit (expense) | 24,366 | (24,638) | (272) | Basic and diluted net loss per ordinary share | $ | (1.57) | $ | — | $ | (1.57) |
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
Year Ended December 31, | Change (in thousands) | Change (in percentage) | ||||||||||||||||
2023 | 2022 (As Restated) | Grant income | $ | — | $ | 166 | $ | (166) | (100) | % | ||||||||
License revenue | 1,698 | 6,194 | (4,496) | (73) | % | |||||||||||||
Operating expenses: | Research and development | (130,481) | (117,354) | (13,127) | 11 | % | ||||||||||||
General and administrative | (46,745) | (31,899) | (14,846) | 47 | % | |||||||||||||
Loss on disposal of leasehold improvements | (3,791) | (515) | (3,276) | 636 | % | |||||||||||||
Impairment of operating lease right-of-use assets and related property and equipment | (382) | — | (382) | 100 | % | |||||||||||||
Total operating expenses, net | (179,701) | (143,408) | (36,293) | 25 | % | |||||||||||||
Other income (expense), net | 2,861 | 2,038 | 823 | 40 | % | |||||||||||||
Interest income | 13,505 | 1,708 | 11,797 | 691 | % | |||||||||||||
Interest expense | (45,067) | (8,905) | (36,162) | 406 | % | |||||||||||||
Total other expense, net | (28,701) | (5,159) | (23,542) | 456 | % | |||||||||||||
Net loss before income tax | (208,402) | (148,567) | (59,835) | 40 | % | |||||||||||||
Income tax benefit | 19 | (272) | 291 | (107) | % | |||||||||||||
Net loss attributable to ordinary shareholders | $ | (208,383) | $ | (148,839) | $ | (59,544) | 40 | % |
10-K
bj8xjnzkumx59k0njsvt
21 Mar 24
Annual report
4:55pm
10-K
2hjttqluzkzi
21 Mar 24
Annual report
4:55pm
10-K
1bhw42tp
21 Mar 24
Annual report
4:55pm
10-K
fqkg sjjvmv6opw
21 Mar 24
Annual report
4:55pm
10-K
8ylo57l
21 Mar 24
Annual report
4:55pm
10-K
k3hioi
21 Mar 24
Annual report
4:55pm
10-K
5p4lt
21 Mar 24
Annual report
4:55pm
10-K
uppl9n
21 Mar 24
Annual report
4:55pm
10-K
ayg7qv 7ndnhbr
21 Mar 24
Annual report
4:55pm
10-K
pf1 dmjah90
21 Mar 24
Annual report
4:55pm
10-K
1zldbsuu70
21 Mar 24
Annual report
4:55pm
10-K
qu01t1
21 Mar 24
Annual report
4:55pm
10-K
7opgmpy40
21 Mar 24
Annual report
4:55pm
10-K
os3qburd 5rv75
21 Mar 24
Annual report
4:55pm
10-K
9xjal
21 Mar 24
Annual report
4:55pm